Jane Ann Nohl Division of Hematology, University of Southern California Keck School of Medicine, Los Angeles, Calif., USA.
Acta Haematol. 2014;131(4):202-7. doi: 10.1159/000354820. Epub 2013 Nov 27.
We retrospectively reviewed the outcome of 20 consecutive subjects with refractory/relapsed acute myeloid leukemia (AML; 9 refractory and 11 relapsed) treated at our institution with a fludarabine, cytarabine and etoposide (FCE) salvage regimen. Of 20 patients with refractory/relapsed AML, 15 (75%) achieved complete remission (CR)/CR with incomplete peripheral blood count recovery (CRi), including 14 CR and 1 CRi. The 4- and 8-week treatment-related mortality (TRM) for all patients during reinduction was 0 and 5%, respectively. Eight of 15 patients (53%) who successfully achieved CR were able to undergo allogeneic hematopoietic stem cell transplantation with a 0% non-relapse mortality rate. FCE is a new, well-tolerated, anthracycline-free regimen, which has a promising activity in relapsed/refractory AML and is associated with low TRM in this high-risk population.
我们回顾性分析了本机构采用氟达拉滨、阿糖胞苷和依托泊苷（FCE）挽救方案治疗的 20 例难治/复发急性髓系白血病（AML；9 例难治，11 例复发）患者的结果。20 例难治/复发 AML 患者中，15 例（75%）获得完全缓解（CR）/不完全外周血细胞计数恢复的完全缓解（CRi），包括 14 例 CR 和 1 例 CRi。所有患者在再诱导期间的 4 周和 8 周治疗相关死亡率（TRM）分别为 0%和 5%。15 例成功获得 CR 的患者中，有 8 例（53%）能够接受异基因造血干细胞移植，且无复发病死率为 0%。FCE 是一种新的、耐受性良好、不含蒽环类药物的方案，在复发/难治性 AML 中具有良好的疗效，在该高危人群中 TRM 较低。
